A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody

ACS Nano

Volumn 8, Issue 3, 2014, Pages 2064-2076

  Aluri, Suhaas Rayudu ^a   Shi, Pu ^a   Gustafson, Joshua A ^a   Wang, Wan ^a   Lin, Yi An ^b   Cui, Honggang ^b   Liu, Shuanglong ^c   Conti, Peter S ^a,c,d   Li, Zibo ^c   Hu, Peisheng ^c   Epstein, Alan L ^c   Mackay, John Andrew ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Johns Hopkins University   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Department of Pathology Keck School of Medicine University of Southern California ^*  (United States)

Author keywords

apoptosis; b cell lymphomas; biodistribution; elastin like polypeptides; hyper cross linking; lipid rafts; nanoworms; Rituxan; Rituximab anti CD20; tumor xenograft

Indexed keywords

ACTIVATION ANALYSIS; CELL CULTURE; CHAINS; ESCHERICHIA COLI; MONOCLONAL ANTIBODIES; NANOSTRUCTURES; PATIENT TREATMENT; POLYMERS; PROTEINS; TRANSMISSION ELECTRON MICROSCOPY; TUMORS;

B-CELL LYMPHOMA; BIODISTRIBUTIONS; ELASTIN-LIKE POLYPEPTIDES; HYPER-CROSS-LINKING; LIPID RAFT; NANOWORMS; RITUXAN; RITUXIMAB ANTI-CD20; TUMOR XENOGRAFTS;

CELL DEATH;

NANOPARTICLE; POLYMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; HUMAN; METHODOLOGY; MOLECULAR GENETICS; NANOMEDICINE; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; TEMPERATURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MOLECULAR SEQUENCE DATA; NANOMEDICINE; NANOPARTICLES; POLYMERS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; SINGLE-CHAIN ANTIBODIES; TEMPERATURE;

EID: 84897012596     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn403973g     Document Type: Article

References (50)

1. Holliger, P.; Hudson, P. J. Engineered Antibody Fragments and the Rise of Single Domains Nat. Biotechnol. 2005, 23, 1126-1136
2. Melmed, G. Y.; Targan, S. R.; Yasothan, U.; Hanicq, D.; Kirkpatrick, P. Certolizumab Pegol Nat. Rev. Drug Discovery 2008, 7, 641-642
3. Nelson, A. L. Antibody Fragments: Hope and Hype mAbs 2010, 2, 77-83
4. Weisser, N. E.; Hall, J. C. Applications of Single-Chain Variable Fragment Antibodies in Therapeutics and Diagnostics Biotechnol. Adv. 2009, 27, 502-520
5. Qian, X.; Peng, X. H.; Ansari, D. O.; Yin-Goen, Q.; Chen, G. Z.; Shin, D. M.; Yang, L.; Young, A. N.; Wang, M. D.; Nie, S. In Vivo Tumor Targeting and Spectroscopic Detection with Surface-Enhanced Raman Nanoparticle Tags Nat. Biotechnol. 2008, 26, 83-90
6. Rudnick, S. I.; Adams, G. P. Affinity and Avidity in Antibody-Based Tumor Targeting Cancer Biother. Radiopharm. 2009, 24, 155-161
7. King, D. J.; Turner, A.; Farnsworth, A. P. H.; Adair, J. R.; Owens, R. J.; Pedley, R. B.; Baldock, D.; Proudfoot, K. A.; Lawson, A. D. G.; Beeley, N. R. A. et al. Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments Cancer Res. 1994, 54, 6176-6185
8. Yokota, T.; Milenic, D. E.; Whitlow, M.; Schlom, J. Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms Cancer Res. 1992, 52, 3402-3408
9. Cumber, A. J.; Ward, E. S.; Winter, G.; Parnell, G. D.; Wawrzynczak, E. J. Comparative Stabilities In Vitro and In Vivo of a Recombinant Mouse Antibody Fvcys Fragment and a Bisfvcys Conjugate J. Immunol. 1992, 149, 120-126
10. Schneider, D. W.; Heitner, T.; Alicke, B.; Light, D. R.; McLean, K.; Satozawa, N.; Parry, G.; Yoo, J.; Lewis, J. S.; Parry, R. In Vivo Biodistribution, Pet Imaging, and Tumor Accumulation of 86y- and 111in-Antimindin/Rg-1, Engineered Antibody Fragments in Lncap Tumor-Bearing Nude Mice J. Nucl. Med. 2009, 50, 435-443
11. Müller, D.; Karle, A.; Meißburger, B.; Höfig, I.; Stork, R.; Kontermann, R. E. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin J. Biol. Chem. 2007, 282, 12650-12660
12. Yang, K.; Basu, A.; Wang, M.; Chintala, R.; Hsieh, M. C.; Liu, S.; Hua, J.; Zhang, Z.; Zhou, J.; Li, M. et al. Tailoring Structure-Function and Pharmacokinetic Properties of Single-Chain Fv Proteins by Site-Specific Pegylation Protein Eng., Des. Sel. 2003, 16, 761-770
13. Howlader, N.; Noone, A. M.; Krapcho, M.; Garshell, J.; Neyman, N.; Altekruse, S. F.; Kosary, C. L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Lewis, D. R.; Chen, H. S.; Feuer, E. J.; Cronin, K. A. SEER Cancer Statistics Review, 1975-2010; National Cancer Institute: Bethesda, MD, 2013; http://seer.cancer.gov/csr/1975-2010/.
14. Coiffier, B.; Lepage, E.; Briére, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P. et al. Chop Chemotherapy Plus Rituximab Compared with Chop Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma N. Engl. J. Med. 2002, 346, 235-242
15. Fitoussi, O.; Belhadj, K.; Mounier, N.; Parrens, M.; Tilly, H.; Salles, G.; Feugier, P.; Ferme, C.; Ysebaert, L.; Gabarre, J. et al. Survival Impact of Rituximab Combined with Acvbp and Upfront Consolidation Autotransplantation in High-Risk Diffuse Large B-Cell Lymphoma for Gela Haematologica 2011, 96, 1136-1143
16. Webber, D. Lymphoma Mabs Rivalry Continues Nat. Biotechnol. 1998, 16, 1000-1001
17. Sousou, T.; Friedberg, J. Rituximab in Indolent Lymphomas Semin. Hematol. 2010, 47, 133-142
18. Weiner, G. J. Rituximab: Mechanism of Action Semin. Hematol. 2010, 47, 115-123
19. Zhang, N.; Khawli, L. A.; Hu, P.; Epstein, A. L. Generation of Rituximab Polymer May Cause Hyper-Cross-Linking-Induced Apoptosis in Non-Hodgkin's Lymphomas Clin. Cancer Res. 2005, 11, 5971-5980
20. Unruh, T. L.; Li, H.; Mutch, C. M.; Shariat, N.; Grigoriou, L.; Sanyal, R.; Brown, C. B.; Deans, J. P. Cholesterol Depletion Inhibits Src Family Kinase-Dependent Calcium Mobilization and Apoptosis Induced by Rituximab Crosslinking Immunology 2005, 116, 223-232
21. Roda, J. M.; Byrd, J. C. Fçriiia Role in Rituximab Efficacy Blood 2007, 110, 2220
22. Semac, I.; Palomba, C.; Kulangara, K.; Klages, N.; van Echten-Deckert, G.; Borisch, B.; Hoessli, D. C. Anti-CD20 Therapeutic Antibody Rituximab Modifies the Functional Organization of Rafts/Microdomains of B Lymphoma Cells Cancer Res. 2003, 63, 534-540
23. Deans, J. P.; Li, H.; Polyak, M. J. CD20-Mediated Apoptosis: Signalling through Lipid Rafts Immunology 2002, 107, 176-182
24. Jazirehi, A. R.; Bonavida, B. Cellular and Molecular Signal Transduction Pathways Modulated by Rituximab (Rituxan, Anti-CD20 Mab) in Non-Hodgkin's Lymphoma: Implications in Chemosensitization and Therapeutic Intervention Oncogene 2005, 24, 2121-2143
25. Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Wang, Y.; Chang, C.-H. Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics Cancer Res. 2008, 68, 8384-8392
26. Johnson, R. N.; Kopeĉková, P.; Kopeĉek, J. i. Synthesis and Evaluation of Multivalent Branched Hpma Copolymer-Fab? Conjugates Targeted to the B-Cell Antigen CD20 Bioconjugate Chem. 2008, 20, 129-137
27. Urry, D. W. Physical Chemistry of Biological Free Energy Transduction as Demonstrated by Elastic Protein-Based Polymers J. Phys. Chem. B 1997, 101, 11007-11028
28. Schmidt, M.; Stockmayer, W. H. Quasi-Elastic Light Scattering by Semiflexible Chains Macromolecules 1984, 17, 509-514
29. Moffitt, M.; Yu, Y.; Nguyen, D.; Graziano, V.; Schneider, D. K.; Eisenberg, A. Coronal Structure of Star-Like Block Ionomer Micelles: An Investigation by Small-Angle Neutron Scattering Macromolecules 1998, 31, 2190-2197
30. Zhang, N.; Khawli, L. A.; Hu, P.; Epstein, A. L. Lym-1-Induced Apoptosis of Non-Hodgkin's Lymphomas Produces Regression of Transplanted Tumors Cancer Biother. Radiopharm. 2007, 22, 342-356
31. Tobin, E.; Denardo, G.; Zhang, N.; Epstein, A. L.; Liu, C.; Denardo, S. Combination Immunotherapy with Anti-CD20 and Anti-HLA-Dr Monoclonal Antibodies Induces Synergistic Anti-Lymphoma Effects in Human Lymphoma Cell Lines Leuk. Lymphoma 2007, 48, 944-956
32. Rimsza, L. M.; Roberts, R. A.; Miller, T. P.; Unger, J. M.; LeBlanc, M.; Braziel, R. M.; Weisenberger, D. D.; Chan, W. C.; Muller-Hermelink, H. K.; Jaffe, E. S. et al. Loss of MHC Class II Gene and Protein Expression in Diffuse Large B-Cell Lymphoma Is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival Regardless of Other Prognostic Factors: A Follow-up Study from the Leukemia and Lymphoma Molecular Profiling Project Blood 2004, 103, 4251-4258
33. Dahle, J.; Borrebaek, J.; Jonasdottir, T. J.; Hjelmerud, A. K.; Melhus, K. B.; Bruland, O. S.; Press, O. W.; Larsen, R. H. Targeted Cancer Therapy with a Novel Low-Dose Rate Alpha-Emitting Radioimmunoconjugate Blood 2007, 110, 2049-2056
34. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc Receptors Modulate In Vivo Cytotoxicity against Tumor Targets Nat. Med. 2000, 6, 443-446
35. Dayde, D.; Ternant, D.; Ohresser, M.; Lerondel, S.; Pesnel, S.; Watier, H.; Le Pape, A.; Bardos, P.; Paintaud, G.; Cartron, G. Tumor Burden Influences Exposure and Response to Rituximab: Pharmacokinetic-Pharmacodynamic Modeling Using a Syngeneic Bioluminescent Murine Model Expressing Human CD20 Blood 2009, 113, 3765-3772
36. Topcic, D.; Kim, W.; Holien, J. K.; Jia, F.; Armstrong, P. C.; Hohmann, J. D.; Straub, A.; Krippner, G.; Haller, C. A.; Domeij, H. et al. An Activation-Specific Platelet Inhibitor That Can Be Turned On/Off by Medically Used Hypothermia Arterioscler., Thromb., Vasc. Biol. 2011, 31, 2015-2023
37. Dolezal, O.; Pearce, L. A.; Lawrence, L. J.; McCoy, A. J.; Hudson, P. J.; Kortt, A. A. Scfv Multimers of the Anti-Neuraminidase Antibody Nc10: Shortening of the Linker in Single-Chain Fv Fragment Assembled in Vl to Vh Orientation Drives the Formation of Dimers, Trimers, Tetramers and Higher Molecular Mass Multimers Protein Eng., Des. Sel. 2000, 13, 565-574
38. Kortt, A. A.; Dolezal, O.; Power, B. E.; Hudson, P. J. Dimeric and Trimeric Antibodies: High Avidity Scfvs for Cancer Targeting Biomol. Eng. 2001, 18, 95-108
39. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in Cancer Therapy and Diagnosis Adv. Drug Delivery Rev. 2002, 54, 631-651
40. Buzea, C.; Pacheco, I. I.; Robbie, K. Nanomaterials and Nanoparticles: Sources and Toxicity Biointerphases 2007, 2, MR17-MR71
41. Dobrovolskaia, M. A.; Germolec, D. R.; Weaver, J. L. Evaluation of Nanoparticle Immunotoxicity Nat. Nanotechnol. 2009, 4, 411-414
42. Martin, F.; Kearney, J. F. Marginal-Zone B Cells Nat. Rev. Immunol. 2002, 2, 323-335
43. Kraal, G. Cells in the Marginal Zone of the Spleen Int. Rev. Cytol. 1992, 132, 31-74
44. Aichele, P.; Zinke, J.; Grode, L.; Schwendener, R. A.; Kaufmann, S. H. E.; Seiler, P. Macrophages of the Splenic Marginal Zone Are Essential for Trapping of Blood-Borne Particulate Antigen but Dispensable for Induction of Specific T Cell Responses J. Immunol. 2003, 171, 1148-1155
45. Demoy, M.; Andreux, J. P.; Weingarten, C.; Gouritin, B.; Guilloux, V.; Couvreur, P. Spleen Capture of Nanoparticles: Influence of Animal Species and Surface Characteristics Pharm. Res. 1999, 16, 37-41
46. Moghimi, S. M.; Hunter, A. C.; Andresen, T. L. Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective Annu. Rev. Pharmacol. Toxicol. 2012, 52, 481-503
47. Meibohm, B.; Zhou, H. Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics J. Clin. Pharmacol. 2012, 52, 54S-62S
48. Hassouneh, W.; Christensen, T.; Chilkoti, A. Elastin-Like Polypeptides as a Purification Tag for Recombinant Proteins Curr. Protoc. Protein Sci. 2010, 61, 6.11.1-6.11.16
49. Slee, E. A.; Zhu, H.; Chow, S. C.; MacFarlane, M.; Nicholson, D. W.; Cohen, G. M. Benzyloxycarbonyl-Val-Ala-Asp (Ome) Fluoromethylketone (Z-Vad.Fmk) Inhibits Apoptosis by Blocking the Processing of Cpp32 Biochem. J. 1996, 315 (Pt 1) 21-24
50. Janib, S. M.; Liu, S.; Park, R.; Pastuszka, M. K.; Shi, P.; Moses, A. S.; Orosco, M. M.; Lin, Y. A.; Cui, H.; Conti, P. S. et al. Kinetic Quantification of Protein Polymer Nanoparticles Using Non-Invasive Imaging Integr. Biol. 2013, 5, 183-194